Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma
Status:
Completed
Trial end date:
2020-04-08
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of radium-223
dichloride that can be given to patients with osteosarcoma.
Radium-223 chloride is designed to work like radiation therapy in cells that are actively
making bone. It is designed to target new bone growth in and around bone cancer and may kill
cancer cells.